BRAF and melanoma: miR-204-5p and miR-211-5p have high expression levels in A375 melanoma cells resistant to the B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) inhibitor vemurafenib, compared to parental cells.